Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1168498 | 0.89 | KDM4E (0.32) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL618564 | 0.83 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL1167851 | 0.80 | KDM4E (0.38) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL618905 | 0.79 | BRD4 (0.30) | — | |
| SCHEMBL1167633 | 0.77 | MEN1 (0.35) | KDM4EALDH1A1 | |
| SCHEMBL617799 | 0.73 | PDE4A (0.31) | — | |
| SCHEMBL1168014 | 0.71 | NPC1 (0.32) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL409429 | 0.71 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL617789 | 0.71 | PTGS2 (0.34) | — | |
| SCHEMBL3587025 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090603-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORPORATION (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140045795-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-8598366-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORPORATION (US) | 2013-12-03 | — | — | US | disclosed |
| US-20120289483-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-8269017-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-09-18 | — | — | US | disclosed |
| US-20110059893-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2011-03-10 | — | — | US | disclosed |
| US-7884094-B2 | antiproliferative agents such as 2-amino-N-(2-methoxy-5-[3- (3,4,5-trimethoxy-phenyl)- isoxazol-4-yl)-phenyl)-3- phenylpropanamide, that inhibit tubulin polymerization and/or target vasculature, usefeul for the treatment of cancer | SYNTA PHARMACEUTICALS CORP. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20100093670-A1 | Compounds for the treatment of angiogenesis | SYNTA PHARMACEUTICALS CORP. | 2010-04-15 | — | — | US | disclosed |
| EP-2059250-A2 | COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | Synta Pharmaceuticals Corporation (US) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008033449-A2 | COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20060217389-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045795-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PDGFRB 186/4885KDM4E 2492/4885ALDH1A1 1872/4885 |
| US-20100093670-A1 | Compounds for the treatment of angiogenesis | FLT4, FLT1, TEK | PDGFRB 46/4885KDM4E 3414/4885ALDH1A1 414/4885 |
| US-20060217389-A1 | Compounds for the treatment of proliferative disorders | RB1, MKI67, MAPRE1 | PDGFRB 186/4885KDM4E 2492/4885ALDH1A1 1872/4885 |
| US-20120289483-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PDGFRB 186/4885KDM4E 2492/4885ALDH1A1 1872/4885 |
| US-20110059893-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PDGFRB 186/4885KDM4E 2492/4885ALDH1A1 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.